Respirology Search

Respirology

Respirology

Home News Diseases Conferences Special Reports Multimedia

IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Idiopathic%20pulmonary%20fibrosis News

News

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Pearl Toh, 20200925150000

Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.

Antireflux drug not as beneficial in idiopathic pulmonary fibrosis treatment

20200921140000

While gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF), treatment with a proton pump inhibitor does not appear to have any bearing on mortality and hospitalization outcomes among IPF patients, according to real-world data.

Serum HMGB1 predicts onset, severity of AE-IPF

20200320110000

Increased levels of serum high-mobility group box 1 (HMGB1) is associated with earlier onset of acute exacerbation (AE) in stable idiopathic pulmonary fibrosis (IPF) patients and shorter survival in those with AE-IPF, a recent study has shown. This signifies that HMGB1 predicts the acute deterioration of IPF.

Chronic viral infection a risk factor for idiopathic pulmonary fibrosis

20191219090000

Persistent or chronic viral infections, such as Epstein-Barr virus and cytomegalovirus, may promote the development, but not exacerbation, of idiopathic pulmonary fibrosis, according to the results of a meta-analysis.

Molecular breath analysis helps speed up screening for IPF

20190524110000

Real-time exhaled breath analysis using secondary electrospray ionization-mass spectrometry has validated previous findings of elevated lung tissue amino acid levels in idiopathic pulmonary fibrosis (IPF), claims a new study, suggesting that online breath analysis can be a practical tool for rapid screening for IPF.

Age, family aggregation, haematological abnormalities predict telomere shortening in IPF patients

20190125120000

Patients with sporadic idiopathic pulmonary fibrosis (IPF) aged <60 years and who have nonspecific immunological or haematological abnormalities are at increased risk of telomere shortening, as well as present a poorer prognosis, according to a study.

Pirfenidone may protect against progression, death in idiopathic pulmonary fibrosis

20181212140000

Treatment with pirfenidone may lead to significantly reduced risks of multiple progression events and death in patients with idiopathic pulmonary fibrosis, according to a study.

INPULSIS-ON validates long-term safety of nintedanib for IPF

Roshini Claire Anthony, 20181004140209

INPULSIS-ON*, the open-label extension of the phase III INPULSIS trials, demonstrated the safety of nintedanib over a long-term period of treatment in patients with idiopathic pulmonary fibrosis (IPF).

Glucocorticoids may confer adverse outcomes in patients with suspected IPF

20180402090000

There have been a substantial number of severe adverse events (SAE) and a faster decrease in forced vital capacity (FVC) in patients with possible idiopathic pulmonary fibrosis (posIPF) taking steroid therapy, a new study has shown.

Pulmonary hypertension risk in CPFE linked to summed extents of ILD, emphysema

20171231100000

Patients with combined pulmonary fibrosis and emphysema (CPFE) are likely to develop pulmonary hypertension, and this likelihood may be explained by the summed extents of interstitial lung disease (ILD) and emphysema, according to a study.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!

Gefapixant cuts frequency of chronic coughs in 2 large studies

Pearl Toh, 18 Sep 2020

Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.

Brensocatib tackles exacerbations in bronchiectasis

Roshini Claire Anthony, 4 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

How to ward off medication errors: Experts' perspectives

Pearl Toh, 18 Jan 2020

Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.